United Therapeutics Executive and Leadership Team

Harsh Hurkat, the Senior Analyst - Chief Financial Officer Org at United Therapeutics, manages complex financial modeling and capital allocation strategies. Hurkat evaluates fiscal performance across North American and European manufacturing sites to ensure optimal resource distribution. By analyzing cost structures within the blow-fill-seal production lines, the Senior Analyst - Chief Financial Officer Org identifies efficiency gains that support long-term profitability. This role requires close collaboration with the broader finance leadership to maintain regulatory compliance and fiscal transparency. Harsh Hurkat drives data-driven decision-making processes that influence the company's investment in sterile unit-dose technology. Through rigorous oversight of operational expenditures, the Senior Analyst - Chief Financial Officer Org secures the financial health necessary for sustained growth in the competitive pharmaceutical landscape. This position remains vital for aligning budgetary goals with the overarching mission of delivering high-quality liquid pharmaceutical products to global markets.

Jeffrey Kase, the Vice President, Chief Information Officer at United Therapeutics, architects the digital infrastructure supporting global manufacturing operations. Kase oversees the integration of advanced automation systems within the blow-fill-seal facilities to ensure data integrity and process precision. By implementing secure, scalable cloud solutions, the Vice President, Chief Information Officer enables seamless communication between international production sites and corporate headquarters. This leadership role involves protecting sensitive pharmaceutical data while optimizing supply chain visibility through sophisticated enterprise resource planning tools. Jeffrey Kase drives the digital transformation strategy, ensuring that all technological deployments meet stringent FDA and EMA cybersecurity standards. Through the modernization of internal networks, the Vice President, Chief Information Officer facilitates efficient collaboration across diverse biotechnology and consumer health teams. Kase maintains a robust technical environment that empowers the company to scale production capabilities while upholding the highest levels of product sterility and operational excellence.

Gil Golden, the Chief Medical Officer at United Therapeutics, directs clinical strategy and medical affairs for the company's diverse portfolio of liquid dosage forms. Golden oversees the scientific validation of nasal sprays, eye drops, and other sterile unit-dose products to ensure alignment with international clinical trial requirements. By providing medical oversight during the formulation development phase, the Chief Medical Officer guarantees that all products meet rigorous safety and efficacy standards. This role involves frequent engagement with regulatory bodies to navigate the complexities of pharmaceutical approval processes across global markets. Gil Golden drives the medical vision, ensuring that patient convenience and therapeutic outcomes remain central to the development of new drug delivery systems. Through the leadership of medical teams, the Chief Medical Officer supports the transition of products from clinical research to commercial-scale production. Golden maintains a focus on scientific integrity, which strengthens the company's reputation as a trusted partner for biotechnology firms and healthcare brands.

Marc Lorber, the Senior Vice President and Chief Medical Officer, Lung Biotechnology, PBC at United Therapeutics, leads specialized medical initiatives focused on advanced respiratory therapies. Lorber oversees the clinical development pipeline, ensuring that innovative liquid formulations address critical unmet needs in lung health. By coordinating with research teams, the Senior Vice President and Chief Medical Officer, Lung Biotechnology, PBC translates complex scientific data into actionable clinical strategies. This role requires deep expertise in navigating the regulatory landscape for sterile pharmaceutical products intended for pulmonary delivery. Marc Lorber drives the medical direction for lung-focused projects, ensuring that all manufacturing processes adhere to the highest quality standards. Through the management of clinical partnerships, the Senior Vice President and Chief Medical Officer, Lung Biotechnology, PBC facilitates the efficient progression of therapies from early-stage development to market availability. Lorber ensures that the company's commitment to patient-centric innovation remains the cornerstone of all medical activities within the lung biotechnology division.

Alyssa Friedrich, the Executive Vice President & Chief People Officer at United Therapeutics, directs human capital strategy to support a global workforce across multiple continents. Friedrich oversees talent acquisition, organizational development, and employee engagement initiatives that align with the company's mission of pharmaceutical excellence. By fostering a culture of innovation and safety, the Executive Vice President & Chief People Officer ensures that the manufacturing teams possess the technical expertise required for complex blow-fill-seal operations. This role involves designing comprehensive training programs that maintain strict adherence to international pharmaceutical guidelines. Alyssa Friedrich drives the leadership development pipeline, ensuring that the organization retains top-tier talent capable of navigating the evolving demands of the biotechnology industry. Through the implementation of robust performance management systems, the Executive Vice President & Chief People Officer supports the operational efficiency of the entire company. Friedrich maintains a focus on building a diverse and inclusive environment that empowers employees to contribute to the successful delivery of life-enhancing pharmaceutical products.